Waystar to Report Q4 and FY 2025 Financial Results on February 17, 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 5d ago

0mins

WAY+0.7%

Should l Buy WAY?

Source: PRnewswire

Earnings Report Schedule: Waystar Holding Corp. will release its Q4 and FY 2025 financial results before market open on February 17, 2026, which is expected to positively impact investor confidence.
Conference Call Details: The company will hold a conference call at 8:30 a.m. Eastern Time on the same day to provide real-time financial data analysis, enhancing transparency and attracting more investor interest.
Webcast Availability: The conference call will be available via live audio webcast on Waystar's investor relations website, with an archived version for those unable to listen live, further improving information accessibility for investors.
Client Base and Market Impact: Waystar serves over 30,000 clients, representing more than 1 million providers, processing over 7.5 billion healthcare payment transactions, showcasing its leadership and significant market influence in the healthcare payment sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy WAY?" and start using high-conviction signals backed by rigorous historical data.

WAY

$24.3+Infinity%1D

Analyst Views on WAY

Wall Street analysts forecast WAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WAY is 47.81 USD with a low forecast of 40.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Analyst Rating

16 Buy

1 Hold

0 Sell

Strong Buy

Current: 24.130

Low

40.00

Averages

47.81

High

54.00

Current: 24.130

Low

40.00

Averages

47.81

High

54.00

Mizuho

Outperform

downgrade

$50 -> $42

2026-02-04

New

Reason

Mizuho

Price Target

$50 -> $42

AI Analysis

2026-02-04

New

downgrade

Outperform

Reason

Mizuho lowered the firm's price target on Waystar to $42 from $50 and keeps an Outperform rating on the shares. The firm trimmed targets in the healthcare technology space citing competitive risk.

Leerink

Outperform

initiated

$43

2026-02-02

Reason

Leerink

Price Target

$43

2026-02-02

initiated

Outperform

Reason

Leerink initiated coverage of Waystar with an Outperform rating and $43 price target. The firm sees Waystar as well-positioned to drive ongoing growth through its broad reach into the market that gives a latent opportunity for further cross-penetration, with additional upside potential from customer expansion. The recent Iodine acquisition advanced the company's AI capabilities while also broadening its end-to-end functionality, offering a one-stop-shop environment for health systems, Leerink adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WAY

Unlock Now

About WAY

Waystar Holding Corp. provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. The Company’s enterprise-grade platform, Waystar, streamlines the complex processes. It leverages internally developed artificial intelligence (AI) as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers. Its software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. The Company’s clients utilize its software to manage pre-encounter workflows, such as eligibility checks and prior authorization approvals, as well as mid- and post-encounter workflows, such as co-pay collection, claims submission and monitoring, and payer remittances.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Is Waystar Capable of Competing with Increasing Rivals?

4 days agoMarketbeat

Company Overview: Waysstar Holding Corp. has established a strong reputation in the healthcare and cloud computing sectors, offering powerful software-as-a-service (SaaS) solutions that integrate payer networks with electronic health records.
Market Competition: The company faces increasing competition from similar firms like Phreesia Inc. and Doximity Inc., which may impact its market share, as Waysstar's shares have declined by 40% over the past year.
Financial Performance: Despite recent challenges, analysts predict growth across multiple metrics for Waysstar, including earnings and share price, with a reported net revenue retention of 113% for the latest quarter.
Acquisitions and Growth Strategy: Waysstar is expanding through acquisitions, including its recent purchase of Iodine Software, which is expected to enhance its market presence and revenue generation capabilities.

Waystar Achieves Best in KLAS for Patient Access for Over a Decade

4 days agoPRnewswire

Industry Recognition: Waystar has been named Best in KLAS for Patient Access, extending its streak of consecutive honors to over a decade, reflecting its outstanding performance in addressing healthcare financial challenges and solidifying its leadership in healthcare payment software.
Financial Challenge Mitigation: Healthcare providers spend over $10 billion annually navigating complex payer authorization requirements, and Waystar's platform significantly reduces denial rates caused by front-end issues through real-time intelligence and autonomous workflows, enhancing client financial returns.
Efficiency Gains: By integrating real-time visibility into insurance coverage with automated authorization, Waystar achieves a 55% reduction in eligibility-related denials and up to 90% auto-approval rates, thereby increasing provider revenue and improving patient access to care.
Revenue Capture: Waystar aids providers in uncovering unknown insurance coverage before care begins, achieving a 55% discovery rate, and combined with pre-service estimation, accelerates collections and protects revenue, further enhancing patient satisfaction.

Waystar Recognized as Best in KLAS for Patient Access

4 days agoNewsfilter

Industry Recognition: Waystar has been awarded Best in KLAS® for Patient Access for over a decade, reflecting its outstanding performance in addressing financial challenges in healthcare payments and solidifying its leadership position in the industry.
Financial Challenge Response: Healthcare providers spend over $10 billion annually navigating complex payer authorization requirements, and Waystar's AI platform significantly enhances revenue recovery efficiency, enabling providers to get paid faster and more accurately.
Automation Authorization Benefits: By integrating real-time visibility into insurance coverage, Waystar achieves a 55% reduction in eligibility-related denials and up to 90% auto-approval rates, increasing provider revenue while improving the patient experience.
Insurance Coverage Discovery: Waystar aids providers in uncovering unknown insurance coverage before care begins, achieving a 55% discovery rate, and combined with pre-service estimation, accelerates collections and protects revenue, further enhancing patient satisfaction.